Replimune’s shares crater as FDA rejects melanoma drug Fierce Biotech Replimune skin cancer therapy rejected by FDA, a sign of regulators’ hardened stance statnews.com Replimune drug rejected by FDA; Omega raises $647M biotech fund Yahoo Finance Replimmune Plummets Following FDA’s Surprise Rejection of Melanoma Treatment BioSpace Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment Barron’s Source link
Read More »